Format

Send to

Choose Destination
Ann Hematol. 2019 May;98(5):1259-1266. doi: 10.1007/s00277-018-3576-2. Epub 2019 Jan 12.

Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.

Huang H1,2, Zhang L3,4, Jiang Y3,4, Liu S3,4, Jin Z3,4, Chen J3,4, Xiao X3,4, Ruan J5,6,7, Zhang X8, Wu D9,10.

Author information

1
Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. huanghaiwen@suda.edu.cn.
2
Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. huanghaiwen@suda.edu.cn.
3
Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.
4
Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China.
5
Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. jruan@med.cornell.edu.
6
Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. jruan@med.cornell.edu.
7
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York-Presbyterian Hospital, 1305 York Ave., 7th Fl, New York, NY, USA. jruan@med.cornell.edu.
8
Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, No. 1017 Dongmen North Road, Shenzhen, 518020, Guangdong, China. zhangxinyou0518@sina.com.
9
Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. wudepei@medmail.com.cn.
10
Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. wudepei@medmail.com.cn.

Abstract

The aim of this study is to determine whether the modified BuCy (semustine, cytarabine, busulfan, and cyclophosphamide, mBuCy) conditioning regimen can be safely used as an alternative to the SEAM (semustine, etoposide, cytarabine, and melphalan) regimen by comparing the efficacy and toxicity of the mBuCy and SEAM regimens. We matched 34 pairs of patients with regard to disease status at the time of autologous stem cell transplantation (auto-SCT). We found no significant difference in the time of platelet engraftment between the two groups. Furthermore, neutrophil engraftment was somewhat faster in the mBuCy group than in the SEAM group (median: 9 days vs 10 days, p = 0.015). With regard to toxicity, the incidence of nausea/vomiting, hepatic impairment, renal impairment, pulmonary infection, and treatment-related mortality (TRM) was similar between the two groups. In addition, compared to patients conditioned with SEAM, patients conditioned with mBuCy were less likely to develop mucositis and diarrhea (p = 0.027; p = 0.050). The 2-year progression-free survival (PFS) rates in the mBuCy and SEAM groups were 79% and 70% (p = 0.378), respectively, and the 2-year overall survival (OS) rates were 81% and 78.0%, respectively (p = 0.789). These analyses showed that the mBuCy conditioning regimen was well tolerated and can be used as an alternative to the SEAM regimen for lymphoma.

KEYWORDS:

Autologous stem cell transplantation; High-dose chemotherapy; Lymphoma; Modified BuCy; SEAM

PMID:
30635767
DOI:
10.1007/s00277-018-3576-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center